Enjoy complimentary customisation on priority with our Enterprise License!
The motion sickness drugs market size is estimated to grow at a CAGR of 4.43% between 2022 and 2027. The market size is forecast to increase by USD 136.49 million. The growth of the market depends on several factors, including the availability of over-the-counter (OTC) drugs, the availability of motion sickness drugs in multiple dosage forms, and growing travel and tourism worldwide.
This motion sickness drugs market report extensively covers market segmentation by product (antihistamines and anticholinergics), distribution channel (offline and online), and geography North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
The availability of over-the-counter (OTC) drugs is notably driving the market growth, although factors such as the launch of generics may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The availability of over-the-counter (OTC) drugs is notably driving the market growth. The global motion sickness drug market is largely served by generic drugs, available both by prescription and over-the-counter. Anticholinergics and antihistamines are considered first-line treatments for controlling and preventing symptoms associated with motion sickness. Several antihistamines are available over the counter and can be used by pediatric patients. These drugs are used primarily to prevent symptoms of motion sickness, not as a treatment. OTC medicines are medicines sold directly to patients or consumers without a doctor's prescription. The availability of these OTC medicines increases their availability and affordability, allowing patients the freedom to self-medicate symptoms associated with mild illness. In addition, the availability of OTC medicines reduces the financial burden associated with drug treatment, as prescriptions are no longer required to purchase these medicines.
Antihistamines are commonly used to prevent and treat motion sickness. First-generation antihistamines include diphenhydramine, dimenhydrinate, meclizine, chlorpheniramine, and promethazine. Second-generation antihistamines include cetirizine and fexofenadine. However, they are not as effective as first-generation antihistamines because they have insufficient central cholinergic activity. The over-the-counter availability of antihistamines has increased the acceptance of antihistamines among patients suffering from motion sickness, thereby driving the growth of the market.
The increased penetration of online channels is the major trend shaping the market. Online drug sales have become increasingly popular in recent years due to their convenience. The COVID-19 pandemic has increased the demand for medicines such as motion sickness medicine through online channels. The rise of telemedicine and virtual consultations has made it easier for patients to receive prescriptions online.
Online platforms offer an easy and convenient way for consumers to purchase medicines from the comfort of their own homes. With the prevalence of technology and the internet, more and more people are adopting e-commerce platforms for pharmaceuticals such as motion sickness remedies, which is expected to drive the growth of the global motion sickness remedies market during the forecast period.
The launch of generics may impede the growth of the market. The introduction of generic drugs in recent years has adversely affected the growth of the global motion sickness drug market. After the introduction of generic drugs, the branded version will be marketed. Generic drugs are cheaper drugs that contain the same active ingredients as the original drug. These drugs enter the market shortly after branded drugs lose their patent exclusivity.
After patent exclusivity is lost, generic product competition increases, leading to lower sales of branded drugs as generic competitors enter the market at lower prices for the same products. This also increases the threat of new market entrants, which in turn impacts the market position of incumbent players. Once these generic drugs are introduced in developed countries, they reach developing countries in a short period of time. Such incidents are estimated to adversely affect the markets of developing countries during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Motion Sickness Drugs Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories: The company offers motion sickness drug called Avomine tablet composed of Promethazine.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the antihistamines segment will be significant during the forecast period. This segment includes cinnarizine, promethazine hydrochloride, promethazine thecate, and meclizine. First-generation antihistamines have antiallergic, antitussive, antipruritic, and antiemetic effects. The antiemetic effect was attributed to the blockade of histamine 1 receptors (H1) and muscarinic receptors. All four drugs have similar pharmacological activity. However, there are no comparative studies.
Get a glance at the market contribution of various segments View the PDF Sample
The antihistamines segment was valued at USD 275.69 million in 2017 and continued to grow until 2021. The over-the-counter availability of antihistamines has improved the availability and affordability of antihistamines for the general public. Various antihistamines are available to prevent and treat motion sickness. In particular, antihistamines with central cholinergic inhibitory properties have been shown to be effective in preventing or treating motion sickness. This fact suggests that the action of antihistamines on motion sickness is not due to histamine-blocking effects but due to peripheral and central anticholinergic effects. First-generation antihistamines act both centrally and peripherally. Thus, they are widely used by patients suffering from motion sickness, which is driving the growth of the segment.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. This high proportion is due to the existence of large pharmaceutical companies offering both branded and generic motion sickness medications and the existence of an adequate regulatory framework for new drug approval in the region. Additionally, tourism and adventure sports that can cause motion sickness are on the rise in the region, increasing the demand for motion sickness remedies.
The rising disposable income of people has led more and more patients to opt for treatment, contributing to the growth of the North American market. Moreover, increasing focus on investment in R&D activities by major vendors to maintain their market position is expected to have a positive impact on the market in the coming years. Pfizer and Mylan are among the leading players in the region.
This report forecasts the contribution of all the segments to the growth of the market. In addition, we have included the COVID-19 impact and the recovery strategies for each segment. The outbreak of COVID-19 had negatively impacted the growth of the regional market in 2020 and 2021. Lockdowns imposed by governments in the United States, Canada, Mexico, and other countries in 2020 and early 2021 disrupted the supply chain of the motion sickness medicine market in the region, impacting the production and distribution of motion sickness medicines. Customers had limited purchasing power, which negatively impacted market growth. However, in 2021, with the start of a vaccination campaign, the lockdown was lifted and operations resumed. Such factors led to moderate growth in the motion sickness remedy market in North America.
The motion sickness drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Technavio categorizes the global motion sickness drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent pharmaceuticals market covers products and companies engaged in the R and D or production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.
Motion Sickness Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
160 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.43% |
Market growth 2023-2027 |
USD 136.49 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
3.83 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Amneal Pharmaceuticals Inc., Baxter International Inc., CVS Health Corp., DM Pharma Marketing Pvt. Ltd., GlaxoSmithKline Plc, Hylands, Lupin Ltd., Merck KGaA, Myungmoon Pharm Co. Ltd., Novartis AG, Perrigo Co. Plc, Prestige Consumer Healthcare Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Tivic Health Systems Inc., Viatris Inc., WellSpring Pharmaceutical Corp., Zenomed Healthcare Pvt. Ltd., and Zydus Lifesciences Ltd. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.